CHD5 may be a promising novel bio-marker for the diagnosis of lung cancer patients

Abstract

Background Chromodomain helicase DNA binding protein 5 (CHD5) is a new tumor suppressor gene in various types of cancer. And it is still not clear about the role of CHD5 in lung cancer. In this study, we aim to assess diagnostic value of CHD5 in patients with lung cancer. Methods CHD5 expression in 108 lung cancer serum samples and 65 healthy controls were determined by quantitative Real-Time PCR (qRT-PCR). A receiver operating characteristic (ROC) curve was established to analyze the effect of CHD5 in the diagnosis of lung cancer. Results The expression of CHD5 was significantly decreased in lung cancer samples compared with the healthy controls (P < 0.0001). Advanced TNM stage (P = 0.020), gender (P = 0.001) and smoking history (P = 0.000) were associated with the decreased CHD5 expression. Besides, the results of ROC analysis showed that the area under ROC curve (AUC) was 0.855 with a sensitivity of 87.1% and a specificity of 81.3%. Conclusions In conclusion, this study suggested that CHD5 expression is down-regulated in lung cancer. Furthermore, CHD5 expression could be a potential diagnosis bio-marker in lung cancer patients.